Association of MMP9, HsCRP, and ESR with 5-ASA Treatment Duration and Disease Activity Based on Truelove and Witts Criteria in Patients with Diagnosed Ulcerative Colitis
), Titong Sugihartono(2), Muhammad Miftahussurur(3),
(1) Internal Medicine Department, dr. Soetomo General Academic Hospital, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia
(2) Gastroenterohepatology Division, Internal Medicine Department, dr. Soetomo General Academic Hospital, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia
(3) Gastroenterohepatology Division, Internal Medicine Department, dr. Soetomo General Academic Hospital, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia
Corresponding Author
Abstract
Background: The American College of Gastroenterology (ACG) currently recommends the Truelove and Witts scoring system for evaluating Ulcerative Colitis (UC) disease activity. Inflammatory markers such as Matrix Metallopeptidase 9 (MMP-9), High-sensitivity C-Reactive Protein (HsCRP), and Erythrocyte Sedimentation Rate (ESR) have previously been shown to correlate with intestinal inflammation. To evaluate the association of MMP-9, HsCRP, and LED with disease activity and treatment duration in UC according to the Truelove and Witts criteria.
Methods: An observational analytic study with a cross-sectional design was conducted involving subjects with UC diagnosed pathologically and receiving 5-ASA therapy at the Gastroenterohepatology Outpatient Department of Dr. Soetomo Hospital. MMP-9, HsCRP, and ESR serum levels were measured. The disease activity was determined based on the Truelove and Witts criteria. Analysis was done by spearman's correlation. P-values and correlation coefficients (r) were presented.
Results: Among the 31 subjects, the majority were female (67.7%) with an average age of 46.84 years. Approximately 35.5% subjects had been treated for more than 6 months. The MMP-9 and HsCRP serum levels were above normal range (71% and 93.5% subjects, respectively). The majority (74.2%) of the subjects had normal ESR levels. Among the investigated inflammatory markers, only ESR levels significantly had a very weak positive correlation (p=0.010; r=0.004).
Conclusion: ESR serves as an effective biomarker for UC disease activity compared to MMP-9 and HsCRP. Further study is warranted to explore the role of these biomarkers in UC management.
Keywords
References
Fakhoury M, Al-Salami H, Negrulj R, Mooranian A. Inflammatory bowel disease: clinical aspects and treatments. JIR. 2014;7:113–20.
Mustika S, Triana N. with Ulcerative Colitis at Dr. Saiful Anwar Malang General Hospital. The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy. 2016;17:16–20.
Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–106.
Hirai F, Matsui T, Aoyagi K, Inoue N, Hibi T, Oshitani N, et al. VALIDITY OF ACTIVITY INDICES IN ULCERATIVE COLITIS: COMPARISON OF CLINICAL AND ENDOSCOPIC INDICES. Digestive Endoscopy. 2010;22(1):39–44.
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–9.
Lin X, Li J, Zhao Q, Feng J rong, Gao Q, Nie J yan. WGCNA Reveals Key Roles of IL8 and MMP-9 in Progression of Involvement Area in Colon of Patients with Ulcerative Colitis. CURR MED SCI. 2018;38(2):252–8.
Marônek M, Marafini I, Gardlík R, Link R, Troncone E, Monteleone G. Metalloproteinases in Inflammatory Bowel Diseases. JIR. 2021;14:1029–41.
Silva BCD, Lyra AC, Rocha R, Santana GO. Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. WJG. 2014;20(28):9458–67.
Betteridge JD, Armbruster SP, Maydonovitch C, Veerappan GR. Inflammatory Bowel Disease Prevalence by Age, Gender, Race, and Geographic Location in the U.S. Military Health Care Population: Inflammatory Bowel Diseases. 2013;19(7):1421–7.
Mikami Y, Tsunoda J, Suzuki S, Mizushima I, Kiyohara H, Kanai T. Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis. Digestion. 2022;104(1):58–65.
Wang Y, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane IBD Group, editor. Cochrane Database of Systematic Reviews. 2016;1–92.
Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Gut Group, editor. Cochrane Database of Systematic Reviews. 2020;2020(8):1–130.
Stabroth-Akil D, Leifeld L, Pfützer R, Morgenstern J, Kruis W. The effect of body weight on the severity and clinical course of ulcerative colitis. Int J Colorectal Dis. 2015;30(2):237–42.
Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, et al. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15(1):7–37.
Jain S, Kedia S, Bopanna S, Yadav DP, Goyal S, Sahni P, et al. Are Truelove and Witts criteria for diagnosing acute severe colitis relevant for the Indian population? A prospective study. Intest Res. 2018;16(1):69–74.
Croft A, Lord A, Radford-Smith G. Markers of Systemic Inflammation in Acute Attacks of Ulcerative Colitis: What Level of C-reactive Protein Constitutes Severe Colitis? Journal of Crohn’s and Colitis. 2022;16(7):1089–96.
Yoon JY, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Correlations of C-reactive Protein Levels and Erythrocyte Sedimentation Rates with Endoscopic Activity Indices in Patients with Ulcerative Colitis. Dig Dis Sci. 2014;59(4):829–37.
Turner D, Mack DR, Hyams J, LeLeiko N, Otley A, Markowitz J, et al. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. Journal of Crohn’s and Colitis. 2011;5(5):423–9.
Osada T, Ohkusa T, Okayasu I, Yoshida T, Hirai S, Beppu K, et al. Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis. J of Gastro and Hepatol. 2008;23(s2):S262–7.
Truelove SC, Witts LJ. CORTISONE IN ULCERATIVE COLITIS. British Medical Journal. (4947–1048):1955.
Cui J, Li X, Zhang Z, Gao H, Li J. Common laboratory blood test immune panel markers are useful for grading ulcerative colitis endoscopic severity. BMC Gastroenterol. 2022;22(540):1–10.
Filippi J, Laharie D, Michiels C, Flamand M, Bouguen G, Nancey S, et al. Efficacy of combination therapy for at least 6 months with thiopurines and infliximab in ulcerative colitis patients in clinical remission: a retrospective multicenter experience. Journal of Crohn’s and Colitis. 2014;1–28.
Zezos P, Kabakchiev B, Weizman AV, Nguyen GC, Narula N, Croitoru K, et al. Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness. Journal of the Canadian Association of Gastroenterology. 2020;3(2):74–82.
Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57(11):1518–23.
Tatsumi Y, Kakimoto K, Hara A, Mizuta N, Numa K, Kinoshita N, et al. Biomarkers for Monitoring of Changes in Disease Activity in Ulcerative Colitis. JCM. 2023;12(22):1–10.
Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology. 1999;117(4):814–22.
Faubion WA, Fletcher JG, O’Byrne S, Feagan BG, De Villiers WJ, Salzberg B, et al. Emerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn’s Disease Activity: Role of Cross-Sectional Imaging. American Journal of Gastroenterology. 2013;108(12):1891–900.
Bai X, Bai G, Tang L, Liu L, Li Y, Jiang W. Changes in MMP‑2, MMP‑9, inflammation, blood coagulation and intestinal mucosal permeability in patients with active ulcerative colitis. Exp Ther Med. 2020;20(1):269–74.
Marshall DC, Lyman SK, McCauley S, Kovalenko M, Spangler R, Liu C, et al. Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer. Cominelli F, editor. PLoS ONE. 2015;10(5):e0127063.
Jakubowska K, Pryczynicz A, Iwanowicz P, Niewiński A, Maciorkowska E, Hapanowicz J, et al. Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases. Gastroenterology Research and Practice. 2016;2016:1–7.
Piechota-Polanczyk A, Włodarczyk M, Sobolewska-Włodarczyk A, Jonakowski M, Pilarczyk A, Stec-Michalska K, et al. Serum Cyclophilin A Correlates with Increased Tissue MMP-9 in Patients with Ulcerative Colitis, but Not with Crohn’s Disease. Dig Dis Sci. 2017;62(6):1511–7.
Yablecovitch D, Kopylov U, Lahat A, Amitai MM, Klang E, Ben-Ami Shor D, et al. Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with quiescent Crohn’s disease, a post hoc analysis. Therap Adv Gastroenterol. 2019;12:1–11.
Ghweil A, Khodeary A, Aziz SP. Diagnostic Value of Fecal Calprotectin and Serum MMP-9 in Diagnosing Disease Activity of Ulcerative Colitis. OJGas. 2018;08(06):234–44.
O’Sullivan S, Gilmer JF, Medina C. Matrix Metalloproteinases in Inflammatory Bowel Disease: An Update. Oral HB, editor. Mediators of Inflammation. 2015;2015:1–19.
Article Metrics
Abstract View
: 41 times
Download : 4 times
DOI: 10.24871/253202432-38
Refbacks
- There are currently no refbacks.
